Asthma-associated risk for COVID-19 development - 03/12/20
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non–type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments.
El texto completo de este artículo está disponible en PDF.Key words : SARS-CoV-2, COVID-19, asthma, endotypes, type 2 asthma, non–type 2 asthma
Abbreviations used : ACE-2, COVID-19, HI, ICS, TMPRSS2
Esquema
| H.R. is funded by the Universities Giessen Marburg Lung Center (UGMLC) and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. C.S. is funded by UGMLC and the German Center for Lung Research, University Hospital Gießen and Marburg research funding according to article 2, section 3 cooperation agreement, the Deutsche Forschungsgemeinschaft (DFG)-funded Sonderforschungsbereich (SFB), Collaborative Research Center (CRC) (grant no. 1021 [C04]), the DFG-funded KFO (Klinische Forschungsgruppe), Germany (grant no. 309 [P10]), and SK 317/1-1 (project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics. |
|
| Disclosure of potential conflict of interest: C. Skevaki received consultancy fees and research funding from Hycor Biomedical and Thermo Fisher Scientific, research funding from Mead Johnson Nutrition, and consultancy fees from Bencard Allergie. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 6
P. 1295-1301 - décembre 2020 Regresar al número
Artículo precedente
- Long-term impact of inhaled corticosteroid use in asthma and chronic obstructive pulmonary disease (COPD): Review of mechanisms that underlie risks
- Aran Singanayagam, Sebastian L. Johnston
- Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis
- Matthew Greenhawt, Marcus Shaker, Julie Wang, John J. Oppenheimer, Scott Sicherer, Corinne Keet, Keri Swaggart, Matthew Rank, Jay M. Portnoy, Jonathan Bernstein, Derek K. Chu, Chitra Dinakar, David Golden, Carolyn Horner, David M. Lang, Eddy S. Lang, David A. Khan, Jay Lieberman, David Stukus, Dana Wallace
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.